MIPI Molecular Insight Pharmaceuticals (MM)

Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Molecular Insight Pharmaceuticals, Inc. (Nasdaq:MIPI). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com

About SMR:

Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php

The Skymark Research logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6683

About Molecular Insight Pharmaceuticals, Inc. (Nasdaq:MIPI)

Molecular Insight Pharmaceuticals, Inc. (Nasdaq:MIPI) is a clinical-stage biopharmaceutical company and pioneer in molecular medicine. The Company is focused on the discovery and development of targeted therapeutic and imaging radiopharmaceuticals for use in oncology. Molecular Insight has five clinical-stage candidates in development.

SMR Disclosure:

Skymarkresearch.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Skymark Research has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, www.skymarkresearch.com, for complete risks and disclosures.

CONTACT:  Skymark Research

          Dylan Boyle

          480-626-1911

          info@skymarkresearch.com